Somatostatin Receptor 2 and 5 Expressions in Gastroenteropancreatic Neuroendocrine Tumors in Turkey

Yerci, Omer; Sehitoglu, Ibrahim; Ugras, Nesrin; Cubukcu, Erdem; Yuce, Suleyman; Bedir, Recep; Cure, Erkan

추천

검색

자료유형: 학술저널

저자정보: Yerci, Omer (Department of Pathology, Faculty of Medicine, Uludag University) Sehitoglu, Ibrahim (Department of Pathology, Faculty of Medicine, Recep Tayyip Erdogan University) Ugras, Nesrin (Department of Pathology, Faculty of Medicine, Uludag University) Cubukcu, Erdem (Department of Medical Oncology, Faculty of Medicine, Uludag University) Yuce, Suleyman (Department of Internal Medicine, Faculty of Medicine, Recep Tayyip Erdogan University) Bedir, Recep (Department of Pathology, Faculty of Medicine, Recep Tayyip Erdogan University) Cure, Erkan (Department of Internal Medicine, Faculty of Medicine, Recep Tayyip Erdogan University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제10호

발행연도: 2015.1

수록면: 4,377 - 4,381 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Gastroenteropancreatic neuroendocrine tumors (GNs) are slow growing and although their incidence has increased in recent years, they are relatively rarely seen. Somatostatin analogues are used in the treatment of GNs that express somatostatin receptor (SR). We aimed to investigate the expression of SR2 and SR5 in GNs. Materials and Methods: In this study the expression of SR2 and SR5 was investigated immunohistochemically in 49 cases (26 males, 23 females) diagnosed and graded with GN according to the World Health Organization classification 2010. Results: The percentage of SR2 staining was 91.0% in grade 1, 82.8% in grade 2 and 100% in grade 3. On the other hand, the percentage of SR5 staining was 81.8% % in grade 1, 60.0% in grade 2 and 0% in grade 3. According to the tumor localization, the percentages of SR2 expression were as follows: pancreas 85.7%, stomach 100%, small bowel 70%, appendix 85.7% and rectum 100%. The percentages of SR5 expression were: pancreas 61,9%, stomach 37.5%, small bowel 70%, appendix 71.5% and rectum 66.6%. There was a significant negative correlation between ki67 percentage and SR5 expression (r=-0.341, p=0.016). Conclusions: In this study, GNs were found to highly express SR2 and SR5. Although the expression of SR2 and SR5 changed according to tumor localization, the expression of SR2 was higher than the expression of SR5 in GN. There was a significant negative correlation between ki67 and SR5. Accordingly, SR5 may be a prognostic indicator of GN.

#Gastroenteropancreatic neuroendocrine tumors #somatostatin receptor 2 #somatostatin receptor 5 #ki67

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!